Aquila Diagnostic Systems Inc. Releases Independent Trial Results For Its AccutasVET Tapeworm Fecal Test
Nov 15, 2017 — Edmonton, Alberta — Aquila Diagnostic Systems Inc. (“Aquila”) is pleased to announce results of an independent laboratory trial for its point-of-care AccutasVET DNA Tapeworm fecal test based on Aquila’s patented molecular diagnostics hydrogel technology.
Aquila Diagnostic Systems Inc. to Present at 2017 Animal Health Investment Forum in Kanas City
Aquila Diagnostic Systems Inc. is pleased to announce that it has been selected to present at the Animal Health Investment Forum, which will take place on August 29th, 2017 in Kansas City Missouri at the Kansas City Convention Center.
Aquila Diagnostic Systems Inc. Raises $1.75 Million Investment in Series A Financing
June 16, 2016 - Aquila Diagnostic Systems Inc., announces the closing of a $1.75 million Series A financing round with Benslie International Ltd.
Aquila Diagnostic Systems Inc. is a privately held Canadian company commercializing its innovative Accutas solution for a point-of-care molecular (DNA/RNA) diagnostic testing system. The patented Accutas solution provides low cost, laboratory quality diagnostics at the point-of-care, eliminating cost and inconvenience of waiting days or weeks for laboratory results to be returned and the subsequent follow-up visit or treatment. Aquila is preparing to enter large markets for the companion animal and food production sectors.
“This new technology... opens up the possibility of using a simple and highly sensitive molecular test at the point-of-care for the diagnosis of malaria and other blood-borne infections.”
Chief Scientific Officer Mark Perkins, Foundation for Innovative New Diagnostics (FIND), Geneva, in a favourable assessment showing Aquila’s Accutas™ diagnostic system achieved results superior to current malaria testing systems.